2m 2m 2m 2m 2m 2m 2m
Standard BioTool (LAB)
NASDAQ
$0.80+$0.008 (+1.00%)
Price as of Jun 23, 2026 7:40 PM EDT- $303.0MMarket Cap
- -35.07%1-Year Change
- Medical DevicesIndustry
Standard BioTool (LAB)
$0.80+$0.008 (+1.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 61.7M -64.65% | 174.4M +64.03% | 106.3M +8.57% | 97.9M -24.99% | |
Cost of Revenue | 29.6M -67.23% | 90.2M +61.33% | 55.9M -8.22% | 60.9M -0.51% | |
Gross Profit | 42.5M -49.51% | 84.3M +67.02% | 50.5M +36.16% | 37.1M -46.59% | |
Sales and Marketing Expense | 109.9M -29.85% | 156.6M +78.90% | 87.5M -23.72% | 114.8M +16.05% | |
Research and Development Expense | -26.0M -58.36% | -62.4M +140.52% | -25.9M -32.60% | -38.5M +1.46% | |
Depreciation and Amortization Expense | 1.7M -60.54% | 4.3M -61.20% | 11.2M -2.85% | 11.5M -3.27% | |
Total Operating Expenses | 152.8M -41.12% | 259.5M +104.25% | 127.0M -40.67% | 214.2M +8.14% | |
Operating Profit | -110.2M -37.09% | -175.2M +128.77% | -76.6M -34.08% | -116.2M +72.26% | |
Interest Income | 9.2M -54.56% | 20.2M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -4.6M +5.45% | -4.3M +13.29% | |
Interest Income and Expense and Net | 9.2M -54.56% | 20.2M +542.28% | -4.6M +5.45% | -4.3M +13.29% | |
Total Nonoperating Income and Expense | 4.4M +184.96% | -5.2M -174.28% | 7.0M +454.82% | 1.3M +155.60% | |
Income before Taxes | -96.7M -30.08% | -138.3M +86.39% | -74.2M -61.54% | -192.9M +203.06% | |
Income Taxes | -37.9M -6,710.12% | 573,000 +26.77% | 452,000 +115.97% | -2.8M -36.02% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | 0 N/A | |
Net Income | -74.9M -46.07% | -138.9M +86.03% | -74.7M -60.73% | -190.1M +220.91% | |
Net Income from Continuing Operations Applicable to Common | -58.8M -68.18% | -184.9M +149.18% | -74.2M -61.54% | -192.9M +203.06% | |
Basic EPS and Net Income | -0.20 -61.54% | -0.52 -44.68% | -0.94 -61.32% | -2.43 +211.54% | |
Diluted EPS and Net Income | -0.20 -61.54% | -0.52 -44.68% | -0.94 -61.32% | -2.43 +211.54% | |
Basic Weighted Average Shares | 381.6M +8.03% | 353.2M +346.24% | 79.2M +1.09% | 78.3M +3.32% | |
Diluted Weighted Average Shares | 381.6M +8.03% | 353.2M +346.24% | 79.2M +1.09% | 78.3M +3.32% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 120.9M -27.51% | 166.7M +222.47% | 51.7M -36.41% | 81.3M +185.79% | |
Short-Term Investments | 66.7M -47.12% | 126.1M +99.63% | 63.2M -25.20% | 84.5M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 187.6M -35.95% | 292.9M +154.91% | 114.9M -30.70% | 165.8M +482.70% | |
Total Current Assets | 454.3M +20.85% | 375.9M +137.58% | 158.2M -24.23% | 208.8M +189.76% | |
Accumulated Depreciation | 48.2M -34.24% | 73.2M +106.39% | 35.5M +22.25% | 29.0M +8.71% | |
Property and Plant and Equipment and Net | 19.3M -54.71% | 42.6M +75.95% | 24.2M -5.71% | 25.7M -8.50% | |
Total Long-Term Assets | 3.2M -49.94% | 6.3M +175.75% | 2.3M -26.50% | 3.1M -15.72% | |
Total Assets | 567.8M -7.28% | 612.3M +89.54% | 323.1M -17.23% | 390.3M +41.82% | |
Income Taxes Payable | 810,000 -25.07% | 1.1M +28.54% | 841,000 -20.28% | 1.1M -75.63% | |
Total Short-Term Debt | N/A N/A | 0 -100.00% | 59.5M +2,757.90% | 2.1M -69.54% | |
Total Current Liabilities | 108.3M +64.37% | 65.9M -39.73% | 109.3M +151.66% | 43.4M -12.36% | |
Total Long-Term Debt | 299,000 0.00% | 299,000 -92.49% | 4.0M -93.66% | 62.8M -2.18% | |
Total Long-Term Liabilities | 1.2M -82.55% | 7.0M +553.71% | 1.1M +10.82% | 961,000 +8.96% | |
Total Liabilities | 143.5M +2.02% | 140.6M -12.04% | 159.9M -0.41% | 160.5M -11.13% | |
Retained Earnings | -1.3B +6.32% | -1.2B +18.48% | -1.0B +8.06% | -926.1M +25.83% | |
Total Stockholders Equity | 424.3M -10.05% | 471.7M +418.62% | -148.1M +81.73% | -81.5M -186.12% | |
Total Shares Outstanding | 386.4M +2.34% | 377.5M +370.55% | 80.2M +0.94% | 79.5M +3.33% | |
Cash Flow | |||||
Cash from Operating Activities | -74.3M -48.18% | -143.5M +231.40% | -43.3M -51.56% | -89.4M +102.83% | |
Capital Expenditures | 8.3M -0.62% | 8.4M +195.13% | 2.8M -25.99% | 3.8M -71.16% | |
Cash from Investing Activities | 27.4M -92.45% | 363.2M +1,694.60% | 20.2M +122.96% | -88.1M +637.71% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 570,000 +100.56% | -102.6M +1,407.06% | -6.8M -102.95% | 230.8M +1,345.94% | |
Financials Ratio | |||||
Gross Margin | 52.07% +7.79% | 48.31% +1.82% | 47.44% +25.42% | 37.83% -28.80% | |
Operating Margin | -178.80% +77.98% | -100.46% +39.46% | -72.03% -39.28% | -118.64% +129.65% | |
Return on Assets | -12.69% -57.25% | -29.69% +41.88% | -20.93% -63.36% | -57.13% +189.30% | |
Return on Equity | -16.72% -80.52% | -85.82% -231.92% | 65.05% +102.25% | -2,895.85% +5,610.99% | |
Revenue Growth | -64.65% -200.97% | 64.03% +647.36% | 8.57% +134.28% | -24.99% +356.47% | |
Current Ratio | 4.19 -26.47% | 5.70 +294.16% | 1.45 -69.89% | 4.81 +230.60% | |
Cash Ratio | 1.12 -55.90% | 2.53 +435.04% | 0.47 -74.73% | 1.87 +226.06% | |
Debt-to-Equity Ratio | N/A N/A | 0.0006 +100.14% | -0.43 -46.14% | -0.80 -206.04% | |
Debt-to-Assets Ratio | N/A N/A | 0.0005 -99.75% | 0.20 +18.22% | 0.17 -35.59% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow